Sarah Cannon Research Institute shared a post on LinkedIn:
“In a new AJMC – The American Journal of Managed Care feature, SCRI’s new President and Chief Medical Officer, David R. Spigel, reflects on two decades of progress that have transformed SCRI from a Nashville‑based research program into a global leader in oncology research.
Dr. Spigel, who first joined SCRI in 2003, now steps into a role shaped by a legacy of innovation established by Howard A. ‘Skip’ Burris III. With Dr. Burris’ retirement in December, longtime physician leaders have stepped into new roles that reinforce SCRI’s scientific strength:
- Melissa Johnson, now Chief Scientific Officer, continues to lead SCRI’s lung cancer research program.
- Erika Hamilton, now Chief Development Officer of Late Phase, continues her leadership in breast cancer research.
Across interviews with AJMC, Drs. Spigel, Johnson, and Hamilton emphasized a shared belief: the science has never been more exciting and the need for community‑based trial access has never been greater.
Read more about SCRI’s leadership, the momentum in oncology research, and why expanding trial access remains at the heart of our mission.”
Erika Hamilton, Chair, Executive Committee, Breast and Breast Program Lead at Sarah Cannon Research Institute, shared Sarah Cannon Research Institute’s post, adding:
“Excited to see Sarah Cannon Research Institute’s leadership and research efforts highlighted in this AJMC feature. In my new role as Chief Development Officer of Late Phase Research, I’m especially inspired by how technology and genomics are transforming trial access.
This is truly one of the most exciting times in cancer research and I’m grateful to be part of a team focused on ensuring patients can participate in innovative trials where they live.”
More posts about Sarah Cannon Research Institute.